CG
VRNA

Cutler Group’s Verona Pharma VRNA Stock Holding History

Cutler Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1K Buy
+1,000
New +$17.3K ﹤0.01% 2132
2023
Q4 		– Sell
-500
Closed -$1K – 4412
2023
Q3 		$1K Buy
+500
New +$9.63K ﹤0.01% 3672
2023
Q1 		– Sell
-17,200
Closed -$3K – 4797
2022
Q4 		$3K Buy
+17,200
New +$229K ﹤0.01% 3559

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Cutler Group's VRNA Position: Q1 2024 in Review

Cutler Group reduced its Verona Pharma (VRNA) stake by 51% in Q1 2024, selling an estimated $3.63K and leaving 200 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Cutler Group first reported a position in VRNA in Q3 2020 and has held it in 9 quarters since. The position peaked at $54K in Q4 2022. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

  • Cutler Group held 200 shares of Verona Pharma worth $3K as of Q1 2024.
  • Cutler Group sold 210 Verona Pharma shares in Q1 2024, an estimated $3.63K.
  • Verona Pharma made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1775 holding.
  • Cutler Group first reported a position in Verona Pharma in Q3 2020 and has held it in 9 quarters since.
  • Cutler Group's Verona Pharma position peaked at $54K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.